Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 15 Apr 2025 |
| The Helsinki Court of Appeal sentenced a member of Orion's Board of Directors to a fine for a securities market information offence | 10 Apr 2025 |
| Orion publishes Interim Report for January-March 2025 and holds a webcast on 23 April 2025 | 9 Apr 2025 |
| Orion Corporation: Organising meeting of the Board of Directors | 3 Apr 2025 |
| Decisions taken by Orion Corporation's Annual General Meeting on 3 April 2025 | 3 Apr 2025 |